Danish researchers and cardiologists have been awarded 473 million kroner by the Novo Nordisk Foundation to investigate heart failure with preserved ejection fraction (HFpEF). The nationwide collaborative project, known as “Capture,” will be led by Herlev and Gentofte Hospital with participation from major hospitals across Denmark.

The research aims to improve understanding and treatment of HFpEF, a complex syndrome affecting the heart, lungs, liver, fatty tissue, muscles, and kidneys. Approximately half of all heart failure cases are HFpEF, affecting around two percent of the adult population and expected to increase in the coming years.

The “Capture” project will involve inviting citizens between 50 and 90 years old, meeting specific criteria, for diagnosis and further investigation, with an expected 5,000 people diagnosed with HFpEF.

Bodil Ørkild, Vice Director at Herlev and Gentofte Hospital, believes “Capture” will significantly impact heart patients and the healthcare system by providing greater disease understanding and treatment insights. Mads Krogsgaard Thomsen, CEO of the Novo Nordisk Foundation, emphasized the project’s importance due to its scope and innovative approach, potentially leading to improved treatment and assistance for more individuals.

The Novo Nordisk Foundation’s funding originates from profits of companies it owns, primarily Novo Nordisk and Novonesis, through the investment company Novo Nordisk Holding. This grant marks the foundation’s largest investment in a clinical research project.